Knight Therapeutics Announces Exclusive License Agreement with AstraZeneca for Movantik/Moventig(R) in Canada and Israel
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor